In tumor immunology, dendritic cells (DCs) serve as key antigen‐presenting cells, and the expression levels of surface molecules directly influence their activation state and ability to stimulate effector T cells.[6, 7] Upregulation of these molecules enhances antigen uptake and processing by DCs and strengthens interactions with T cells, thereby promoting T‐cell activation and proliferation.[8, 9] Previous studies have shown that pan‐PI3K inhibition markedly increases the expression of CD80, CD86, MHC‐I, and MHC‐II in DCs. The gene discussed is CD86; the disease is neoplasm.